- Senti Biosciences (SNTI, Financial) to host a conference call and webcast on April 28, 2025, to discuss SENTI-202 Phase 1 clinical data.
- The event will coincide with the presentation at the American Association for Cancer Research (AACR) Annual Meeting.
- Webcast access available on Senti Bio's website and archived for 90 days.
Senti Biosciences, Inc. (SNTI), a clinical-stage biotechnology company, has announced it will host a conference call and webcast to discuss new Phase 1 clinical data for its SENTI-202 therapy. The announcements are set for Monday, April 28, 2025, at 8:30 AM ET, during the American Association for Cancer Research (AACR) Annual Meeting.
The presentation will be led by the company's CEO and Co-Founder Timothy Lu, MD, PhD, and President, Head of R&D, and Chief Medical Officer Kanya Rajangam, MD, PhD. SENTI-202 is a first-in-class off-the-shelf Logic-Gated selective CD33 OR FLT3 NOT EMCN CAR NK cell therapy, currently enrolling patients in a Phase 1 clinical trial. The company's proprietary Gene Circuit platform is being used to develop next-generation cell and gene therapies that target both liquid and solid tumor indications.
Interested participants and investors can join the conference call by dialing (877) 524-8416 for domestic calls or +1 (412) 902-1028 for international calls. Additionally, the webcast will be accessible on the company’s website under the Investors section, and it will remain available for 90 days following the live event.
Senti Bio is committed to leveraging its Gene Circuit platform to create therapies that enhance precision and control, aiming to selectively kill cancer cells while sparing healthy ones. The company continues to advance its pipeline through strategic collaborations and is exploring the potential of its platform beyond oncology.
